Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lipitor Payments Under Medicaid Vary By 12% – IG

Executive Summary

Some states paid as much as 12% more than the lowest paying states for identical units of Pfizer's Lipitor in fiscal year 2001, a report from the HHS Office of Inspector General concludes

You may also be interested in...



Texas Considering Suits To Compel Average Manufacturer Price Reporting

Drug manufacturers may face lawsuits for failing to provide average manufacturer price information to states that have requested it

Zyprexa Medicaid Cost Highlight Of OIG’s Mental Health Rx Spending Report

The HHS Office of Inspector General's report on Medicaid spending for mental health drugs singles out Lilly's Zyprexa (olanzapine) as a particularly costly product for the program

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel